DE69628290D1 - Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle - Google Patents

Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle

Info

Publication number
DE69628290D1
DE69628290D1 DE69628290T DE69628290T DE69628290D1 DE 69628290 D1 DE69628290 D1 DE 69628290D1 DE 69628290 T DE69628290 T DE 69628290T DE 69628290 T DE69628290 T DE 69628290T DE 69628290 D1 DE69628290 D1 DE 69628290D1
Authority
DE
Germany
Prior art keywords
lipidizing
compositions
methods
lipid
hydrophilic molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69628290T
Other languages
English (en)
Other versions
DE69628290T2 (de
Inventor
Wei-Chiang Shen
M Ekrami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of DE69628290D1 publication Critical patent/DE69628290D1/de
Publication of DE69628290T2 publication Critical patent/DE69628290T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
DE69628290T 1995-01-25 1996-01-25 Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle Expired - Fee Related DE69628290T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34971795A 1995-01-25 1995-01-25
US349717 1995-01-25
US08/524,362 US5907030A (en) 1995-01-25 1995-09-05 Method and compositions for lipidization of hydrophilic molecules
US524362 1995-09-05
PCT/US1996/001052 WO1996022773A1 (en) 1995-01-25 1996-01-25 Methods and compositions for lipidization of hydrophilic molecules

Publications (2)

Publication Number Publication Date
DE69628290D1 true DE69628290D1 (de) 2003-06-26
DE69628290T2 DE69628290T2 (de) 2004-03-18

Family

ID=26996314

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69628290T Expired - Fee Related DE69628290T2 (de) 1995-01-25 1996-01-25 Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle
DE69637229T Expired - Lifetime DE69637229T2 (de) 1995-01-25 1996-01-25 Lipidisierung hydrophiler Moleküle

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69637229T Expired - Lifetime DE69637229T2 (de) 1995-01-25 1996-01-25 Lipidisierung hydrophiler Moleküle

Country Status (14)

Country Link
US (4) US5907030A (de)
EP (2) EP1327628B1 (de)
JP (1) JP3814294B2 (de)
KR (1) KR100438268B1 (de)
CN (1) CN1139385C (de)
AT (2) ATE371643T1 (de)
AU (1) AU699827B2 (de)
CA (1) CA2211442A1 (de)
DE (2) DE69628290T2 (de)
EA (1) EA000584B1 (de)
ES (1) ES2200051T3 (de)
FI (1) FI973048A (de)
NO (1) NO973403L (de)
WO (1) WO1996022773A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
JP2002515883A (ja) * 1996-09-26 2002-05-28 ユニバーシティ オブ サザン カリフォルニア 親水性分子の脂質化のための方法および組成物
GB9704519D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Compounds
US6093692A (en) * 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
MXPA01011347A (es) * 1999-05-07 2004-06-03 Pharmasol Gmbh Portador de farmaco producido a partir de conjugados de matriz lipida-farmaco (particula lak) para la aplicacion controlada de un agente activo.
WO2000069898A2 (en) 1999-05-14 2000-11-23 Arbor Vita Corporation Molecular interactions in allergy cells
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
BR0212985A (pt) 2001-09-24 2005-08-30 Imp College Innovations Ltd Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
GB0129121D0 (en) * 2001-12-05 2002-01-23 Ic Vec Ltd Compound
JP4733922B2 (ja) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US7285289B2 (en) * 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20080233181A1 (en) * 2002-04-12 2008-09-25 Nagy Jon O Nanoparticle adjuvants for sub-unit vaccines
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US20040151766A1 (en) * 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
US20090074885A1 (en) * 2003-09-08 2009-03-19 Roche Madison Inc. Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells
US20050054612A1 (en) * 2003-09-08 2005-03-10 Monahan Sean D. Delivery by labile hydrophobic modification of drugs
US20080119412A1 (en) 2003-12-23 2008-05-22 Nono Inc. Polypeptides for Modulating Binding of Trp Channel Proteins and Trp- Associated Proteins
US7282590B2 (en) * 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
EP1773878B1 (de) 2004-07-19 2015-03-04 Biocon Limited Insulinoligomerkonjugate, formulierungen und anwendungen davon
EP1695717A1 (de) * 2005-02-23 2006-08-30 Ludwig-Maximilians-Universität Transport Nano- und Makromolecularer Strukturen ins Zytoplasma und in den Zellkern
GB0504857D0 (en) * 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
ATE553124T1 (de) 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP4879988B2 (ja) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
JP2010508271A (ja) * 2006-10-27 2010-03-18 ウェイ‐チャン シェン 脂質化インターフェロンおよびその使用
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
CA2693392A1 (en) 2007-07-09 2009-01-15 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
WO2009050738A2 (en) * 2007-10-16 2009-04-23 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
WO2009059984A2 (en) * 2007-11-06 2009-05-14 F. Hoffmann-La Roche Ag Reversible hydrophobization of antitumor drugs for enhanced first-pass drug uptake
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
GB201001333D0 (en) 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
GB201107118D0 (en) 2011-04-27 2011-06-08 Imp Innovations Ltd Method of diagnosis and prognosis
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US20170137486A1 (en) 2014-05-23 2017-05-18 Imperial Innovations Limited Peptide yy (pyy) analogues
GB201720187D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
GB201908424D0 (en) 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
JP2024501467A (ja) 2020-12-11 2024-01-12 アイピー２アイピーオー イノベ－ションズ リミテッド 新規化合物
IL303969A (en) 2021-01-24 2023-08-01 David Forrest Michael ugh

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63246382A (ja) * 1987-04-02 1988-10-13 Karupisu Shokuhin Kogyo Kk ビオチニル試薬及びそれを用いるビオチニル化法
US5599903A (en) * 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5679643A (en) * 1987-10-13 1997-10-21 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
IE911351A1 (en) * 1990-04-23 1991-10-23 Res Corp Technologies Inc Soluble tyrosine and cysteine source for total parenteral¹nutrition
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
JP3091270B2 (ja) * 1990-09-28 2000-09-25 協和醗酵工業株式会社 美白化粧料
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5635380A (en) * 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
CA2260761C (en) 1996-06-25 2011-05-03 Nico Johannes Christiaan Maria Beekman Vaccine comprising antigens bound to carriers through labile bonds

Also Published As

Publication number Publication date
DE69628290T2 (de) 2004-03-18
WO1996022773A1 (en) 1996-08-01
NO973403L (no) 1997-09-17
US20040054132A1 (en) 2004-03-18
US6225445B1 (en) 2001-05-01
EP0820285A4 (de) 1998-04-22
KR19980701667A (ko) 1998-06-25
EP0820285B1 (de) 2003-05-21
JPH11500108A (ja) 1999-01-06
FI973048A0 (fi) 1997-07-18
CN1139385C (zh) 2004-02-25
US7052704B2 (en) 2006-05-30
NO973403D0 (no) 1997-07-23
EP1327628A3 (de) 2003-08-13
EA199700143A1 (ru) 1997-12-30
FI973048A (fi) 1997-09-16
JP3814294B2 (ja) 2006-08-23
US5907030A (en) 1999-05-25
DE69637229D1 (de) 2007-10-11
AU4769296A (en) 1996-08-14
US5936092A (en) 1999-08-10
EP0820285A1 (de) 1998-01-28
ATE371643T1 (de) 2007-09-15
ATE240729T1 (de) 2003-06-15
EP1327628B1 (de) 2007-08-29
CN1175902A (zh) 1998-03-11
EP1327628A2 (de) 2003-07-16
CA2211442A1 (en) 1996-08-01
ES2200051T3 (es) 2004-03-01
AU699827B2 (en) 1998-12-17
EA000584B1 (ru) 1999-12-29
DE69637229T2 (de) 2008-05-15
KR100438268B1 (ko) 2004-09-04

Similar Documents

Publication Publication Date Title
DE69628290D1 (de) Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle
DK0833620T3 (da) FGFR3, en markør for mesenkymale progenitorceller
DE69635609D1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
ES2177789T3 (es) Peptidos antagonistas de lhrh.
BR0305074A (pt) Composições cosméticas com alta afinidade
BR0010721A (pt) Composições de neisserias combinadas
EP1832599A3 (de) Albuminfusionsproteine
DE50014571D1 (de) Träger-pharmaka-konjugate
DE69531342D1 (de) Avidin-biotin immunokonjugate
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
ATE308563T1 (de) Aktives hedgehog-protein-konjugat, verfahren zur herstellung und verwendung
WO1996016084A3 (en) A method of identifying cftr-binding compounds useful for activating chloride conductance in animal cells
ATE339186T1 (de) Methode zur herstellung von mikropartikeln enthaltend biologisches material
Miyanishi et al. Electron microscopic study on the location of 23 kDa and 50 kDa fragments in skeletal myosin head
DE69941299D1 (de) Zusammensetzungen und verfahren zur behandlung der polyzystischen nierenkrankheit
Yu et al. Ca super (2+)-mediated GTP-dependent dynamic assembly of bacterial cell division protein FtsZ into asters and polymer networks in vitro
RU94046405A (ru) Птг-соединения и содержащий их фармацевтический состав, способ получения желаемых полипептидов, нуклеотидная последовательность, бактериальный вектор экспрессии, бактериальные хозяйские клетки и составной белок
FR2668036B1 (fr) Procede de tannage des substances proteiques, notamment des substances proteique vegetales telles que les proteines d'oleagineux et substances proteiques tannees obtenues par ce procede.
WORTMAN Comparison of Nonhistone Nuclear Proteins from Mouse Epidermis to Nonhistone Nuclear Proteins from Chemically Induced Papillomas and Carcinomas
EP1220873A1 (de) Neue proteinkomponente und dafür kodierende nukleinsäure

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee